184 related articles for article (PubMed ID: 34242369)
1. Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease.
Kato M; Sugimoto K; Ikeya K; Takano R; Matsuura A; Miyazu T; Ishida N; Tamura S; Tani S; Yamade M; Hamaya Y; Iwaizumi M; Osawa S; Furuta T; Hanai H
PLoS One; 2021; 16(7):e0254548. PubMed ID: 34242369
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.
Bodini G; Giannini EG; Savarino V; Del Nero L; Pellegatta G; De Maria C; Baldissarro I; Savarino E
Scand J Gastroenterol; 2016 Sep; 51(9):1081-6. PubMed ID: 27207330
[TBL] [Abstract][Full Text] [Related]
3. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.
Imaeda H; Takahashi K; Fujimoto T; Bamba S; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A
J Gastroenterol; 2014 Jan; 49(1):100-9. PubMed ID: 23575576
[TBL] [Abstract][Full Text] [Related]
5. Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis.
Yarur AJ; Jain A; Hauenstein SI; Quintero MA; Barkin JS; Deshpande AR; Sussman DA; Singh S; Abreu MT
Inflamm Bowel Dis; 2016 Feb; 22(2):409-15. PubMed ID: 26752470
[TBL] [Abstract][Full Text] [Related]
6. INFLIXIMAB AND ADALIMUMAB SERUM TROUGH CONCENTRATIONS THRESHOLD ASSOCIATED WITH DEEP REMISSION IN INFLAMMATORY BOWEL DISEASE.
Pascual-Marmaneu Ó; Belles-Medall MD; Ferrando-Piqueres R; Almela-Notari P; Mendoza-Aguilera M; Álvarez-Martín T
Farm Hosp; 2021 Aug; 45(5):225-233. PubMed ID: 34806581
[TBL] [Abstract][Full Text] [Related]
7. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
Roblin X; Marotte H; Rinaudo M; Del Tedesco E; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
Clin Gastroenterol Hepatol; 2014 Jan; 12(1):80-84.e2. PubMed ID: 23891927
[TBL] [Abstract][Full Text] [Related]
8. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.
Nakase H; Motoya S; Matsumoto T; Watanabe K; Hisamatsu T; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
Aliment Pharmacol Ther; 2017 Nov; 46(9):873-882. PubMed ID: 28884856
[TBL] [Abstract][Full Text] [Related]
9. Relationship between Serum Adalimumab Levels and Clinical Outcome in the Treatment of Inflammatory Bowel Disease.
Hinojosa J; Muñoz F; Martínez-Romero GJ
Dig Dis; 2019; 37(6):444-450. PubMed ID: 31039560
[TBL] [Abstract][Full Text] [Related]
10. Higher Maintenance Adalimumab Trough Levels are Associated With Achievement of Advanced Remission Targets in Patients With Inflammatory Bowel Disease.
Ritter E; Hirsch A; Isakov NF; Ron Y; Cohen NA; Maharshak N
J Clin Gastroenterol; 2021 Oct; 55(9):810-814. PubMed ID: 33060434
[TBL] [Abstract][Full Text] [Related]
11. Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease.
Morita Y; Imaeda H; Nishida A; Inatomi O; Bamba S; Sasaki M; Tsujikawa T; Sugimoto M; Andoh A
J Gastroenterol Hepatol; 2016 Nov; 31(11):1831-1836. PubMed ID: 27043158
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
Tursi A; Mocci G; Allegretta L; Aragona G; Bianco MA; Colucci R; Cuomo A; Della Valle N; Ferronato A; Forti G; Gaiani F; Giorgetti G; Graziani MG; Lofano K; Lorenzetti R; Larussa T; Penna A; Pica R; Pranzo G; Rodino' S; Scarcelli A; Zampaletta C; Bassotti G; Cazzato AI; Chiri S; Clemente V; Cocco A; De' Angelis G; Donnarumma L; Faggiani R; Graziosi C; Le Grazie M; Luzza F; Meucci C; Monterubbianesi R; Pagnini C; Perazzo P; Picchio M; Sacco R; Sebkova L; Serio M; Napolitano D; Pugliese D; Scaldaferri F; Schiavoni E; Turchini L; Armuzzi A; Elisei W; Maconi G; Papa A
Inflamm Bowel Dis; 2023 Mar; 29(3):376-383. PubMed ID: 35579320
[TBL] [Abstract][Full Text] [Related]
13. Leucine-Rich Alpha-2 Glycoprotein May Be Predictive of the Adalimumab Trough Level and Antidrug Antibody Development for Patients with Inflammatory Bowel Disease: A Sub-Analysis of the PLANET Study.
Yanai S; Shinzaki S; Matsuoka K; Mizuno S; Iijima H; Naka T; Kanai T; Matsumoto T
Digestion; 2021; 102(6):929-937. PubMed ID: 34350873
[TBL] [Abstract][Full Text] [Related]
14. Swapping Versus Dose Optimization in Patients Losing Response to Adalimumab With Adequate Drug Levels.
Roblin X; Genin C; Nancey S; Williet N; Veyrard P; Boschetti G; Phelip JM; Berger AE; Killian M; Waeckel L; Flourie B; Paul S
Inflamm Bowel Dis; 2022 May; 28(5):720-727. PubMed ID: 34405867
[TBL] [Abstract][Full Text] [Related]
15. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.
Roblin X; Rinaudo M; Del Tedesco E; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
Am J Gastroenterol; 2014 Aug; 109(8):1250-6. PubMed ID: 24913041
[TBL] [Abstract][Full Text] [Related]
16. One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed.
Tighe D; Hall B; Jeyarajah SK; Smith S; Breslin N; Ryan B; McNamara D
Inflamm Bowel Dis; 2017 Jul; 23(7):1154-1159. PubMed ID: 28486256
[TBL] [Abstract][Full Text] [Related]
17. No Difference of Adalimumab Pharmacokinetics When Dosed at 40 mg Every Week or 80 mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose Intensification.
Paul S; Williet N; Nancey S; Veyrard P; Boschetti G; Phelip JM; Flourie B; Roblin X
Dig Dis Sci; 2021 Aug; 66(8):2744-2749. PubMed ID: 32936345
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
Warman A; Straathof JW; Derijks LJ
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
[TBL] [Abstract][Full Text] [Related]
19. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
[TBL] [Abstract][Full Text] [Related]
20. Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice.
Aguas Peris M; Bosó V; Navarro B; Marqués-Miñana MR; Bastida G; Beltrán B; Iborra M; Sáez-González E; Monte-Boquet E; Poveda-Andrés JL; Nos P
Inflamm Bowel Dis; 2017 Aug; 23(8):1454-1460. PubMed ID: 28708805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
